Recently Approved

August 2008
Pharmaceutical Representative;Aug2008, Vol. 38 Issue 8, p14
The article offers information on medicines approved by the U.S. Food and Drug Administration (FDA) for use in treating various diseases. Accordingly, the FDA has approved Eli Lilly's Cymbalta from for the treatment of fibromyalgia. Moreover, it states that Avodart from GlaxoSmithKline has been cleared for use in combination with Boehringer Ingelheim Pharmaceuticals Inc.'s Flomax for the treatment of symptomatic benign prostatic hyperplasia.


Related Articles

  • NEWSLINE.  // MPR - Pharmacist's Edition;Winter2010/2011, Vol. 4 Issue 4, pA.7 

    The article offers news briefs related to drugs in New York. Boehringer Ingelheim Pharmaceuticals Inc. offers Pradaxa, an oral direct thrombin inhibitor to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. The use of Avandia from GlaxoSmithKline...

  • GlaxoSmithKline: combo drug set to become blockbuster.  // PharmaWatch: Cancer;Aug2010, Vol. 9 Issue 8, p8 

    In this article, the author discusses the U.S. Food and Drug Administration (FDA) approval of GlaxoSmithKline's combination drug Jalyn for the treatment of benign prostatic hyperplasia (BPH). The author emphasizes that Jalyn will face various challenges such as ensuring the reimbursement of the...

  • PROSTATIC ARTERY EMBOLIZATION STUDIES MOVE FORWARD: Phase 3 FDA Trial Starting.  // Radiology Today;Jul2013, Vol. 14 Issue 7, p30 

    The article reports on the preliminary results from the first U.S. prospective trial on prostatic artery embolization, presented by interventional radiologist Sandeep Bagla at the spring's annual meeting of the Society of Interventional Radiology. The study revealed the significant decrease in...

  • BPH treatment device may improve sexual function. Tennant, Scott // Urology Times;4/1/2005, Vol. 33 Issue 4, p11 

    The article focuses on Benign prostatic hyperplasia (BPH) treatment device that may improve sexual function. Not only does a form of microwave thermotherapy for BPH appear to be free of sexual side effects it may actually improve sexual function in men with the disease. In a randomized blinded...

  • GlaxoSmithKline: combo drug set to become blockbuster.  // PharmaWatch: Monthly Review;Aug2010, Vol. 9 Issue 8, p12 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to GlaxoSmithKline's combination drug Jalyn for the treatment of benign prostatic hyperplasia (BPH). The decision of the agency was based on the positive results of clinical trial. The challenges facing...

  • Product Preview.  // Urology Times;Jan2004, Vol. 32 Issue 1, p24 

    Presents various updates on urological drugs and devices. GlaxoSmithKline clinical trial on drug to treat benign prostatic hyperplasia in men; Extension of marketing exclusivity granted by the U.S. Food and Drug Administration to Bayer Pharmaceuticals for its fluoroquinolone antibiotic...

  • Ridgefield Company starts prostate drug campaign. Chuvala, Bob // Fairfield County Business Journal;12/12/2005, Vol. 44 Issue 50, p3 

    The article reports that Ridgefield-based Boehringer-Ingelheim Pharmaceuticals enlisted Earl "The Pearl" Monroe in a campaign to educate men above fifty about benign prostate enlargement. The author informs that the campaign also aims to advertise the company's prescription treatment for benign...

  • New Distribution.  // Drug Topics;9/20/99, Vol. 143 Issue 18, p100 

    Announces the collaboration between Abbott Laboratories and Boehringer Ingelheim Pharmaceuticals to distribute and co-promote Flomax, a benign prostatic hyperplasia treatment from Boehringer Ingelheim. When Flomax was introduced in the United States market; Plans of Abbott to promote and sell...

  • CHAPTER 18: UROLOGICAL DISORDERS.  // Monthly Prescribing Reference;Oct2015, Vol. 31 Issue 10, p293 

    The article offers brief information on the medicinal products indicated for urological disorders from several pharmaceutical companies including Avodart from GlaxoSmithKline, Cardura from Pfizer Inc. and Flomax from Boehringer Ingelheim Pharmaceuticals Inc.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics